Pharmaceutical Pricing and Reimbursement Information (PPRI)

Transcription

1 Pharmaceutical Pricing and (PPRI) GÖG/ÖBIG Sabine Vogler HSWP Meeting, 12 June 2007

2 Pharmaceutical Pricing and - PPRI Rationale Objectives Project organisation Work packages and deliverables Preliminary results & Evaluation

3 Rationale 27 different pharmaceutical pricing and reimbursement systems in the enlarged EU Need for knowledge and analysis of PPRI and exchange of information and experience between policy-makers Previous and ongoing work: Post G10 process WHO ÖBIG studies EURO-MED-STAT EURO DURG Pharmaceutical Forum (Pricing Relative Effectiveness Patient Information)

4 PPRI - Timetable Project proposal submission: May 2004 Project start: Spring 2005 PPRI Conference: 29 June 2007 Project end: Autumn 2007

5 PPRI Objectives Strengthening the networking of the relevant national authorities and institutions in the field of pharmaceuticals in the Member States Assessing the needs of EU and national administration and policymakers with regard to knowledge and information transfer on PPRI Country reports on pharmaceutical pricing and reimbursement ( Pharma Profiles ) Developing indicators for the comparative analysis Dissemination of the project results

6 PPRI - Project organisation Commissioners: European Commission - DG Sanco; Austrian Federal Ministry of Health, Family and Youth Project leaders: GÖG/ÖBIG, WHO Europe Participants at Member State level: competent authorities, Medicines Agencies, Third Party Payers, research institutes at European / international level: EMEA, OECD, DG Enterprise, World Bank Cooperation with other projects and initiatives: EUROMEDSTAT, SOGETI, EASP, Pharmaceutical Forum, MEDEV A network of 46 participating institutions EU Member States + AL, CA, NO, TR

7 PPRI Work packages WP 1: Coordination GÖG/ÖBIG, throughout the whole project WP 2: Dissemination GÖG/ÖBIG, WHO and all PPRI participants - throughout the whole project WP 3: Assessment WHO, presentation of results - April 2006 WP4: Survey WHO, presentation of first Pharma Profiles October 2006 WP 5: Development of comparable indicators GÖG/ÖBIG, presentation - March 2007 WP 6: Comparative Analysis GÖG/ÖBIG, draft comparative analysis - March 2007

8 PPRI WP 1 Coordination Keeping the network active Ensuring information flow (5 Coordination Meetings, Intranet) Active commitment of participants PPRI WP 2 Dissemination PPRI website: Publications Presentations PPRI Conference, Vienna, 29 June 2007

9 PPRI WP 3 Assessment Survey: 101 institutions on national level and 14 on European level Deliverable: Needs Assessment Report Results - Background information on pharmaceutical pricing and reimbursement - Pharmaceutical pricing, reimbursement, cost-containment, evaluation PPRI WP 5 Indicators Analysis of all relevant indicators in the pharmaceutical field Development and approval of a core set of PPRI indicators Deliverable: 21 qualitative and quantitative indicators

10 PPRI WP 4 Survey/1 Deliverable: Pharma Profiles = country profiles on the pharmaceutical pricing and reimbursement Basis: Detailed outline ( Pharma Profile Template ) Overview of the chapters: 1 Background 4 Reimbursement 2 Pharmaceutical System 5 Rational use of pharmaceuticals 3 Pricing 6 Current challenges Common terminology: PPRI glossary (

11 Why do we need a common language? Reference Price System International Referencing External Referencing Margin Mark up ATC 4 Level Cross-Country Price Comparison

12 PPRI WP 4 Survey/2 Authors: PPRI participants Editorial Team Currently 21 Pharma Profiles Pharma Profiles will be available on the PPRI website for downloading / on CD Rom

13 PPRI WP 6 Comparative Analysis/1 Comparable analysis of the country specific results taken from the Pharma Profiles Basis: Core list of PPRI indicators Numerous overview tables and figures Results will be presented at PPRI Conference Part of PPRI Report

14 PPRI WP 6 Comparative Analysis/2 Preliminary results - Pricing Price setting for the reimbursable segment Comparison with prices in other countries Regulations of mark-ups Specific VAT rates Preliminary results - Reimbursement Positive lists Percentage co-payment of reimbursable pharmaceuticals Reference Price System (different methods) Co-payment as a cost-containment measure

15 PPRI Preliminary evaluation/1 Common understanding Common terminology / glossary Indicators for pharmaceuticals Data availability and comparability Gap on hospital market Need for regular updates

16 PPRI Preliminary evaluation/ Accessibility and affordability in the context of cost-containment More exchange of information Keep the network alive

17 PPRI Conference 29 June 2007 Akademie der Wissenschaften Registration: Contact:

18 This paper was produced for a meeting organized by Health & Consumer Protection DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumer Protection DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.